Pharmaceutical companies face growing pressure to engage with biotechnological innovation as biologics, biosimilars, advanced bioprocessing, genomic medicine, precision therapeutics, and research-intensive product development reshape the basis of competition. These innovations can expand therapeutic possibilities, strengthen product differentiation, and support higher-value pharmaceutical manufacturing. Their adoption, however, introduces scientific, operational, financial, and regulatory demands that differ substantially from those associated with conventional pharmaceutical production. Biotechnology therefore represents both a strategic opportunity and a complex organizational transformation challenge. For Saudi pharmaceutical companies, biotechnology adoption is closely connected to healthcare transformation, pharmaceutical localization, industrial diversification, and the development of national life-science capabilities. Access to technology or investment capital alone does not ensure that a firm can evaluate, absorb, implement, and sustain biotechnology-based innovation. Adoption also depends on managerial commitment, R&D capability, workforce competence, regulatory preparedness, knowledge coordination, external collaboration, and implementation discipline. Weakness in any of these areas can delay adoption, increase risk, or limit the value created from biotechnology investments. This article develops a conceptual framework for understanding how organizational readiness and managerial drivers influence biotechnological innovation adoption in Saudi pharmaceutical companies. It treats adoption as a multidimensional organizational process rather than a discrete technology-acquisition decision. The framework explains how internal capabilities and managerial actions combine to shape adoption readiness, implementation quality, and innovation outcomes. The framework integrates insights from pharmaceutical innovation, biotechnology adoption, organizational readiness, strategic management, R&D capability, absorptive capacity, knowledge management, regulatory preparedness, and Saudi healthcare-sector transformation. It distinguishes readiness conditions from managerial drivers while explaining their interdependence during technology evaluation, capability development, partnership formation, regulatory alignment, and implementation. It also incorporates market, regulatory, localization, and healthcare-transformation conditions as contextual forces that may enable or constrain adoption. The resulting structure provides an analytically coherent basis for evaluating biotechnology adoption within Saudi pharmaceutical organizations. The principal contribution is an integrated explanation of how organizational readiness conditions and managerial drivers interact with the Saudi pharmaceutical-sector context. The framework proposes that biotechnology adoption becomes more credible when strategic alignment, scientific capability, financial commitment, workforce preparation, regulatory readiness, and implementation governance reinforce one another. It further argues that managerial action determines whether latent readiness is converted into coordinated adoption activity. This perspective supports more responsible, competitive, and sustainable biotechnology development in the Saudi pharmaceutical sector.
